Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease
| Autor: | Chih Ping Mao, Tal Gilboa, Katrina Nguyen, Quan Zhu, Alana F. Ogata, Maia Norman, Richelle C. Charles, Matthew T. Chang, Gail Newton, Roey Lazarovits, Edward T. Ryan, Maliwan Kamkaew, Adam M. Maley, Travis E. Gibson, David R. Walt, Wayne A. Marasco, Connie Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine viruses Clinical Biochemistry Disease Antibodies Viral medicine.disease_cause Serology 0302 clinical medicine Limit of Detection Medicine viral antigen Antigens Viral serological Coronavirus Aged 80 and over biology Middle Aged Prognosis Hospitalization Intensive Care Units Spike Glycoprotein Coronavirus Disease Progression Female single molecule arrays Antibody Adult Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Article COVID-19 Serological Testing 03 medical and health sciences Antigen Coronavirus Nucleocapsid Proteins Humans Seroconversion longitudinal plasma samples Aged Biochemistry medical SARS-CoV-2 business.industry Biochemistry (medical) COVID-19 Phosphoproteins Protein Subunits 030104 developmental biology Respiratory failure Immunology biology.protein Intubation business 030217 neurology & neurosurgery |
| Zdroj: | Clinical Chemistry |
| ISSN: | 1530-8561 0009-9147 |
| Popis: | Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 21 million people worldwide since August 16, 2020. Compared to PCR and serology tests, SARS-CoV-2 antigen assays are underdeveloped, despite their potential to identify active infection and monitor disease progression. Methods We used Single Molecule Array (Simoa) assays to quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of patients with coronavirus disease (COVID-19). We studied plasma from 64 patients who were COVID-19 positive, 17 who were COVID-19 negative, and 34 prepandemic patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we quantified changes in 31 SARS-CoV-2 biomarkers in 272 longitudinal plasma samples obtained for 39 patients with COVID-19. Data were analyzed by hierarchical clustering and were compared to longitudinal RT-PCR test results and clinical outcomes. Results SARS-CoV-2 S1 and N antigens were detectable in 41 out of 64 COVID-19 positive patients. In these patients, full antigen clearance in plasma was observed a mean ± 95% CI of 5 ± 1 days after seroconversion and nasopharyngeal RT-PCR tests reported positive results for 15 ± 5 days after viral-antigen clearance. Correlation between patients with high concentrations of S1 antigen and ICU admission (77%) and time to intubation (within 1 day) was statistically significant. Conclusions The reported SARS-CoV-2 Simoa antigen assay is the first to detect viral antigens in the plasma of patients who were COVID-19 positive to date. These data show that SARS-CoV-2 viral antigens in the blood are associated with disease progression, such as respiratory failure, in COVID-19 cases with severe disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|